HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Generation and characterization of a novel tetravalent anti-CD22 antibody with improved antitumor activity and pharmacokinetics.

Abstract
The purpose of this study was to prepare a tetravalent anti-human CD22 recombinant antibody with improved antitumor activity and a half life longer than that of its divalent counterpart. We compared the ability of tetravalent vs. divalent antibody to associate/dissociate to/from CD22-positive Daudi cells, to interact with murine and human Fcgamma receptors (FcgammaR), to bind human complement component C1q, to inhibit the growth of tumor cells, to diffuse into various tissues, to be internalized by Daudi cells, to react with human neonatal Fc receptors (FcRn), and to persist in the circulation of normal mice. As compared to the murine or chimeric divalent antibodies, the chimeric tetravalent counterpart has a longer half life in mice. It also has an affinity for FcRns that is identical to that of human IgG. The tetravalent antibody has increased antitumor activity in vitro and completely conserved effector functions (binding to FcgammaR-positive cells and to C1q) in vitro. Despite its 33% higher molecular weight, it penetrates mouse tissues as well as its divalent antibody counterpart. Based on the improved in vitro performance and pharmacokinetics of the tetravalent antibody it will now be tested for its antitumor activity in vivo.
AuthorsXiao-Yun Liu, Laurentiu M Pop, Derry C Roopenian, Victor Ghetie, Ellen S Vitetta, Joan E Smallshaw
JournalInternational immunopharmacology (Int Immunopharmacol) Vol. 6 Issue 5 Pg. 791-9 (May 2006) ISSN: 1567-5769 [Print] Netherlands
PMID16546710 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Histocompatibility Antigens Class I
  • Immunoglobulin G
  • Receptors, Fc
  • Receptors, IgG
  • Sialic Acid Binding Ig-like Lectin 2
  • Complement C1q
  • Fc receptor, neonatal
Topics
  • Animals
  • Antibodies, Monoclonal (chemistry, pharmacokinetics, pharmacology)
  • Antineoplastic Agents (chemistry, pharmacokinetics, pharmacology)
  • Cell Survival (drug effects)
  • Complement C1q (immunology)
  • Female
  • Histocompatibility Antigens Class I (genetics, immunology)
  • Humans
  • Immunoglobulin G (immunology)
  • Mice
  • Mice, Transgenic
  • Receptors, Fc (genetics, immunology)
  • Receptors, IgG (immunology)
  • Sialic Acid Binding Ig-like Lectin 2 (immunology)
  • U937 Cells

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: